Skip to main content
SpringerLink
Log in

Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Ovarian cancer is the first leading cause of mortality in gynecological malignancies. To identify key genes and microRNAs in ovarian cancer, mRNA microarray dataset GSE36668, GSE18520, GSE14407 and microRNA dataset GSE47841 were downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) and microRNAs (DEMs) were obtained using GEO2R. Functional and pathway enrichment analysis were performed for DEGs using DAVID database. Protein–protein interaction (PPI) network was established by STRING and visualized by Cytoscape. Following, overall survival (OS) analysis of hub genes was performed by the Kaplan–Meier plotter online tool. Module analysis of the PPI network was performed using MCODE. Moreover, miRecords was applied to predict the targets of the DEMs. A total of 345 DEGs were obtained, which were mainly enriched in the terms related to cell cycle, mitosis, and ovulation cycle process. A PPI network was constructed, consisting of 141 nodes and 296 edges. Sixteen genes had high degrees in the network. High expression of four genes of the 16 genes was associated with worse OS of patients with ovarian cancer, including CCNB1, CENPF, KIF11, and ZWINT. A significant module was detected from the PPI network. The enriched functions and pathways included cell cycle, nuclear division, and oocyte meiosis. Additionally, a total of 36 DEMs were identified. The expression of KIF11 was negatively correlated with that of has-miR-424 and has-miR-381, and it was also the potential target of two microRNAs. In conclusion, these results identified key genes, which could provide potential targets for ovarian cancer diagnosis and treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262.

    Article  PubMed  Google Scholar 

  2. Wright JD, Shah M, Mathew L, Burke WM, Culhane J, Goldman N, et al. Fertility preservation in young women with epithelial ovarian cancer. Cancer. 2009;115(18):4118–26. doi:10.1002/cncr.24461.

    Article  PubMed  Google Scholar 

  3. Urban N, Drescher C. Potential and limitations in early diagnosis of ovarian cancer. Adv Exp Med Biol. 2008;622:3–14. doi:10.1007/978-0-387-68969-2_1.

    Article  PubMed  Google Scholar 

  4. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer. 2000;89(10):2068–75.

    Article  CAS  PubMed  Google Scholar 

  5. Urban N, Hawley S, Janes H, Karlan BY, Berg CD, Drescher CW, et al. Identifying post-menopausal women at elevated risk for epithelial ovarian cancer. Gynecol Oncol. 2015;139(2):253–60. doi:10.1016/j.ygyno.2015.08.024.

    Article  PubMed  Google Scholar 

  6. Felder M, Kapur A, Gonzalez-Bosquet J, Horibata S, Heintz J, Albrecht R, et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014;13:129. doi:10.1186/1476-4598-13-129.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Vathipadiekal V, Wang V, Wei W, Waldron L, Drapkin R, Gillette M, et al. Creation of a human secretome: a novel composite library of human secreted proteins—validation using ovarian cancer gene expression data and a virtual secretome array. Clin Cancer Res. 2015;21(21):4960–9. doi:10.1158/1078-0432.CCR-14-3173.

    Article  CAS  PubMed  Google Scholar 

  8. Wei SU, Li H, Zhang B. The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer. Biomed Rep. 2016;5(1):41–4. doi:10.3892/br.2016.682.

    PubMed  PubMed Central  Google Scholar 

  9. Bowen NJ, Walker LD, Matyunina LV, Logani S, Totten KA, Benigno BB, et al. Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Med Genom. 2009;2:71. doi:10.1186/1755-8794-2-71.

    Article  Google Scholar 

  10. Elgaaen BV, Olstad OK, Sandvik L, Odegaard E, Sauer T, Staff AC, et al. ZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas and correlate with survival. PLoS One. 2012;7(9):e46317. doi:10.1371/journal.pone.0046317.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, et al. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell. 2009;16(6):521–32. doi:10.1016/j.ccr.2009.10.018.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Elgaaen BV, Olstad OK, Haug KB, Brusletto B, Sandvik L, Staff AC, et al. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. BMC Cancer. 2014;14:80. doi:10.1186/1471-2407-14-80.

    Article  Google Scholar 

  13. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res. 2013;41(Database issue):D991–5. doi:10.1093/nar/gks1193.

    Article  CAS  PubMed  Google Scholar 

  14. da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57. doi:10.1038/nprot.2008.211.

    Article  CAS  Google Scholar 

  15. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43(Database issue):D447–52. doi:10.1093/nar/gku1003.

    Article  PubMed  Google Scholar 

  16. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genom Res. 2003;13(11):2498–504. doi:10.1101/gr.1239303.

    Article  CAS  Google Scholar 

  17. Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinform. 2003;4:2.

    Article  Google Scholar 

  18. Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res. 2009;37(Database issue):D105–10. doi:10.1093/nar/gkn851.

    Article  CAS  PubMed  Google Scholar 

  19. Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012;19(2):197–208. doi:10.1530/ERC-11-0329.

    Article  CAS  PubMed  Google Scholar 

  20. Wan J, Shi F, Xu Z, Zhao M. Knockdown of eIF4E suppresses cell proliferation, invasion and enhances cisplatin cytotoxicity in human ovarian cancer cells. Int J Oncol. 2015;47(6):2217–25. doi:10.3892/ijo.2015.3201.

    PubMed  Google Scholar 

  21. Fang Y, Yu H, Liang X, Xu J, Cai X. Chk1-induced CCNB1 overexpression promotes cell proliferation and tumor growth in human colorectal cancer. Cancer Biol Ther. 2014;15(9):1268–79. doi:10.4161/cbt.29691.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Zhou L, Li J, Zhao YP, Cui QC, Zhou WX, Guo JC, et al. The prognostic value of Cyclin B1 in pancreatic cancer. Med Oncol. 2014;31(9):107. doi:10.1007/s12032-014-0107-4.

    Article  PubMed  Google Scholar 

  23. Avery-Kiejda KA, Bowden NA, Croft AJ, Scurr LL, Kairupan CF, Ashton KA, et al. P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer. 2011;11:203. doi:10.1186/1471-2407-11-203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Kreis NN, Friemel A, Zimmer B, Roth S, Rieger MA, Rolle U, et al. Mitotic p21Cip1/CDKN1A is regulated by cyclin-dependent kinase 1 phosphorylation. Oncotarget. 2016. doi:10.18632/oncotarget.10330.

    Google Scholar 

  25. Tu Y, Kim E, Gao Y, Rankin GO, Li B, Chen YC. Theaflavin-3, 3′-digallate induces apoptosis and G2 cell cycle arrest through the Akt/MDM2/p53 pathway in cisplatin-resistant ovarian cancer A2780/CP70 cells. Int J Oncol. 2016;48(6):2657–65. doi:10.3892/ijo.2016.3472.

    PubMed  PubMed Central  Google Scholar 

  26. Zhou J, Zhao M, Tang Y, Wang J, Wei C, Gu F, et al. The milk-derived fusion peptide, ACFP, suppresses the growth of primary human ovarian cancer cells by regulating apoptotic gene expression and signaling pathways. BMC Cancer. 2016;16:246. doi:10.1186/s12885-016-2281-6.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Volkov VA, Grissom PM, Arzhanik VK, Zaytsev AV, Renganathan K, McClure-Begley T, et al. Centromere protein F includes two sites that couple efficiently to depolymerizing microtubules. J Cell Biol. 2015;209(6):813–28. doi:10.1083/jcb.201408083.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Brendle A, Brandt A, Johansson R, Enquist K, Hallmans G, Hemminki K, et al. Single nucleotide polymorphisms in chromosomal instability genes and risk and clinical outcome of breast cancer: a Swedish prospective case–control study. Eur J Cancer. 2009;45(3):435–42. doi:10.1016/j.ejca.2008.10.001.

    Article  CAS  PubMed  Google Scholar 

  29. Dai Y, Liu L, Zeng T, Zhu YH, Li J, Chen L, et al. Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma. Biochem Biophys Res Commun. 2013;436(4):711–8. doi:10.1016/j.bbrc.2013.06.021.

    Article  CAS  PubMed  Google Scholar 

  30. Zhuo YJ, Xi M, Wan YP, Hua W, Liu YL, Wan S, et al. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer. Int J Mol Med. 2015;35(4):966–72. doi:10.3892/ijmm.2015.2086.

    CAS  PubMed  Google Scholar 

  31. Martens-de Kemp SR, Nagel R, Stigter-van Walsum M, van der Meulen IH, van Beusechem VW, Braakhuis BJ, et al. Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer. Clin Cancer Res. 2013;19(8):1994–2003. doi:10.1158/1078-0432.CCR-12-2539.

    Article  CAS  PubMed  Google Scholar 

  32. Venere M, Horbinski C, Crish JF, Jin X, Vasanji A, Major J, et al. The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma. Sci Transl Med. 2015;7(304):304ra143. doi:10.1126/scitranslmed.aac6762.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Mirzaa GM, Enyedi L, Parsons G, Collins S, Medne L, Adams C, et al. Congenital microcephaly and chorioretinopathy due to de novo heterozygous KIF11 mutations: five novel mutations and review of the literature. Am J Med Genetics Part A. 2014;164A(11):2879–86. doi:10.1002/ajmg.a.36707.

    Article  Google Scholar 

  34. Seo DW, You SY, Chung WJ, Cho DH, Kim JS, Oh JS. Zwint-1 is required for spindle assembly checkpoint function and kinetochore-microtubule attachment during oocyte meiosis. Sci Rep. 2015;5:15431. doi:10.1038/srep15431.

    Article  CAS  Google Scholar 

  35. Endo H, Ikeda K, Urano T, Horie-Inoue K, Inoue S. Terf/TRIM17 stimulates degradation of kinetochore protein ZWINT and regulates cell proliferation. J Biochem. 2012;151(2):139–44. doi:10.1093/jb/mvr128.

    Article  CAS  PubMed  Google Scholar 

  36. Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev. 2015;87:3–14. doi:10.1016/j.addr.2015.05.001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Zuberi M, Mir R, Das J, Ahmad I, Javid J, Yadav P, et al. Erratum to: Expression of serum miR-200a, miR-200b and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features. Clin Transl Oncol. 2015;17(10):840. doi:10.1007/s12094-015-1355-2.

    Article  CAS  PubMed  Google Scholar 

  38. Meng X, Muller V, Milde-Langosch K, Trillsch F, Pantel K, Schwarzenbach H. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget. 2016;7(13):16923–35. doi:10.18632/oncotarget.7850.

    PubMed  PubMed Central  Google Scholar 

  39. Xu S, Tao Z, Hai B, Liang H, Shi Y, Wang T, et al. miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nat Commun. 2016;7:11406. doi:10.1038/ncomms11406.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Xia B, Li H, Yang S, Liu T, Lou G. MiR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression. Tumour Biol. 2016. doi:10.1007/s13277-016-4805-8.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedical Engineering, School of Basic Medical Sciences, Wuhan University, 185 Donghu Road, Wuhan, 430071, Hubei, China

    Zhanzhan Xu, Yu Zhou & Min Zhao

  2. Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China

    Yexuan Cao, Thi Lan Anh Dinh & Jing Wan

Authors
  1. Zhanzhan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yexuan Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thi Lan Anh Dinh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jing Wan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Min Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Min Zhao.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, Z., Zhou, Y., Cao, Y. et al. Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis. Med Oncol 33, 130 (2016). https://doi.org/10.1007/s12032-016-0840-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-016-0840-y

Keywords

Search

Navigation